ClinicalTrials.gg
RecruitingNCT05955365MATRIX-2Updated Nov 16, 2026

Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Drug-eluting Stent Implantation

A Phase 4 interventional study of P2Y12 inhibitor and Aspirin in Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF) and Oral Anticoagulation, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 18 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Insel Gruppe AG, University Hospital Bern · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Nov 16, 2026Site recruiting status changedTitle changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,010
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern — 6 open to participants now, 8 under way, none of them phase 3. Atrial Fibrillation · Insel Gruppe AG, University Hospital Bern.

Planned enrollment
Largest of 10
3,010 · median 208
Started
2023
with 2 others
Phase 4
4 of 19
1 open now
Registered
15th of 19
by date

Among the 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern, this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 in phase 4, and was the 15th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

6 of the 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern, or all of them as a file.
02

Study summary

Patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation require treatment with different antithrombotic drugs. Oral anticoagulants are prescribed to reduce the risk of stroke associated with atrial fibrillation. Antiplatelet substances are prescribed after stent implantation to reduce the risk of adverse cardiac events such as myocardial infarction or stent thrombosis. Treatment with antithrombotic medications can cause bleeding complications, particularly when these substances are combined.

The currently recommended standard strategy consists of treatment with 3 antithrombotic medications for at least 1 week up to one month, followed by treatment with two of these medications for up to 6-12 months after stent implantation. Thereafter, patients usually receive long-term treatment with only one drug, an anticoagulant.

In the monotherapy group of this study, the investigators will investigate a strategy where only one antithrombotic drug will be used at a time. During the first month after stent implantation, the investigators will prescribe an antiplatelet medication, followed by an oral anticoagulant as monotherapy. This strategy might be associated with fewer bleeding complications, while protecting adequately against thrombotic events.

In this study the investigators would like to investigate whether treatment with a single antithrombotic drug ("monotherapy strategy") is associated with benefits compared to the currently recommended combination therapy of antithrombotic medications ("standard-of-care strategy").

Read the detailed description

Background:

The optimal antithrombotic treatment following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) requiring long-term oral anticoagulation remains a matter of debate. In particular, the appropriate intensity and duration of antithrombotic strategies to prevent ischemic events, while mitigating the risk of bleeding complications in this high bleeding risk population during the early peri-procedural period (within 30 days) and thereafter (from 30 days to 1 year) following drug-eluting stent implantation remains unclear.

Aim:

The investigators aim to assess the safety and efficacy of a P2Y12 inhibitor monotherapy regimen for 1 month followed by DOAC monotherapy long-term versus current standard of care consisting of triple antithrombotic therapy for up to one month (aspirin, P2Y12 inhibitor and DOAC) followed by dual antithrombotic therapy (P2Y12 inhibitor and DOAC) for 6 to 12 months and DOAC monotherapy thereafter, in AF patients undergoing PCI indicated for treatment with a DOAC after drug-eluting stent implantation and followed for a period of 12 months.

Methodology:

This investigator-initiated, multi-center, randomized, open-label, blinded evaluation, international clinical trial in 3010 AF patients with indication for long-term oral anticoagulation who have undergone successful PCI with drug-eluting stent implantation. The study will be conducted at approximately 150 sites across Europe and Brazil. Patients will be randomized to the antithrombotic monotherapy (experimental antithrombotic strategy) or the standard of care strategy (control group) in a 1:1 ratio. Randomization is stratified by site, acute coronary syndrome (ACS) within the previous 6 months and CHA2DS2-VASc score ≥4. Patients randomized to the antithrombotic monotherapy treatment receive any of the commercially available oral P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) and immediately discontinue aspirin and DOAC. After 1 month, the P2Y12 inhibitor will be stopped and treatment with a commercially available DOAC will be initiated for the duration of 11 months. Patients randomized to the standard of care strategy will initiate triple therapy for up to 1 month followed by dual anti-thrombotic therapy (consisting of P2Y12 inhibitor for a minimum of 6 and up to 12 months plus DOAC for at least 12 months).

Potential significance:

This is the first study investigation the impact of a short course of P2Y12 inhibitor monotherapy up to 1 month, while omitting clopidogrel non-responders, and temporarily omitting OAC, after stent implantation followed by OAC monotherapy in AF patients undergoing PCI. This sequential monotherapy treatment strategy has solid rational and carries potential to balance bleeding against cardiac and cerebral ischemic risks.

03

Conditions studied

  • Percutaneous Coronary Intervention (PCI)
  • Atrial Fibrillation (AF)
  • Oral Anticoagulation
  • P2Y12 Inhibitor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Atrial fibrillation or flutter with an indication for oral anticoagulation using direct-acting oral anticoagulants (DOACs) for ≥12 months
  • Successful percutaneous coronary intervention in at least 1 lesion within the previous 7 days with no remaining lesions intended for treatment.
  • Free from major adverse events post qualifying PCI, including new onset chest pain suspected to be of ischemic origin, acute or subacute stent thrombosis, new-onset neurological signs or symptoms.
  • Written

Exclusion criteria

Exclusion Criteria:

  • Planned staged percutaneous intervention procedure (Patients can be enrolled after complete coronary revascularization with no remaining lesions intended for treatment. Patients who have or develop indication to percutaneous valve intervention can undergo treatment more than 30 days after qualifying PCI.)
  • Cardioversion for treatment of atrial fibrillation within 1 month prior to inclusion or planned cardioversion
  • AF ablation procedure within 2 months prior to inclusion or planned AF ablation procedure
  • Prior mechanical valvular prosthesis implantation
  • Deep vein thrombosis/pulmonary embolism, at least moderately severe mitral stenosis or other clinical conditions than atrial fibrillation requiring long-term oral anticoagulation
  • Stroke within 1 month prior to randomization
  • Hemodynamic instability (persistent systolic blood pressure below 90 mmHg, continuous infusions of catecholamines, clinical signs of hypoperfusion and/or use of percutaneous left ventricular assist devices)
  • Uncontrolled severe hypertension with a systolic blood pressure (BP) ≥180 mmHg and/or diastolic BP ≥120 mmHg
  • Severe renal impairment with estimated (CrCL) \<15 mL/min or on dialysis
  • Moderate or severe hepatic impairment ( Class B or C) or any hepatic disease associated with coagulopathy
  • Any or for direct oral anticoagulation or dual antiplatelet therapy with aspirin and a P2Y12 inhibitor
  • Any of the following abnormal local laboratory results prior to randomization: count \<50 x109/L or \<8 g/dL
  • Known pregnancy or breast-feeding patients
  • \<1 year due to other severe non-cardiac disease
  • Planned surgery including coronary artery bypass grafting within the next 6 months
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,010 participants (estimated)

Study arms

  • Experimental
    Monotherapy strategy

    Patients randomized to the monotherapy treatment arm receive any of the commercially available oral P2Y12 inhibitors (clopidogrel, prasugrel oder ticagrelor) and immediately discontinue aspirin and DOAC (or will not re-start DOAC after PCI if treatment was temporarily stopped before). After 1 month, the P2Y12 inhibitor will be stopped and treatment with a commercially available DOAC (at investigator's discretion and dosed according to the instructions for use in patients with atrial fibrillation) will be initiated for the duration of 11 months. After completion of the 12-month study regimen (study visit), the patient will receive antithrombotic therapy according to routine care.

    Drug: P2Y12 inhibitor · Drug: DOAC

  • Active comparator
    Standard of care strategy

    Patients randomized to the standard of care, receive DOAC for at least 12 months. In addition, aspirin is administered for up to 1 month after PCI at investigator's discretion and one of the available P2Y12 inhibitors (clopidogrel, prasugrel oder ticagrelor at investigator's discretion) is administered for a minimum of 6 months and up to 12 months after PCI. After completion of the 12-month control arm regimen (study visit), the patients will be treated according to routine care.

    Drug: P2Y12 inhibitor · Drug: Aspirin · Drug: DOAC

Interventions

  • The choice of P2Y12 inhibitor is left at investigator's discretion.

  • Aspirin is administered for up to 1 month after PCI at investigator's discretion

  • DrugDOAC

    The choice of DOAC is left at investigator's discretion.

06

What researchers measure

Primary outcomes

  1. The number of participants with a major adverse cardiac or cerebral events (MACCE), defined as the composite of death from any cause, myocardial infarction, stroke or non-central nervous system (non-CNS) systemic embolism

    Time frame: 12 months

  2. The number of participants with a major or clinically relevant non-major bleeding (MCB), defined according to the International Society of Thrombosis and Haemostasis (ISTH) criteria

    Time frame: 12 months

Secondary outcomes

  1. The incidence of MACCE or MCB

    MACCE, defined as the composite of death from any cause, myocardial infarction, stroke or non-CNS systemic embolism and MCB, defined according to the ISTH criteria

    Time frame: 12 months

  2. The incidence of MACCE or MCB

    MACCE, defined as the composite of death from any cause, myocardial infarction, stroke or non-CNS systemic embolism and MCB, defined according to the ISTH criteria

    Time frame: 15 months

  3. The number of participants with a composite of death from cardiovascular causes, myocardial infarction or stroke

    Time frame: 12 months

  4. The number of participants with a composite of death from cardiovascular causes, myocardial infarction or stroke

    Time frame: 15 months

  5. The number of participants with a composite of death from cardiovascular causes, myocardial infarction, stroke or non-CNS systemic embolism

    Time frame: 12 months

  6. The number of participants with a composite of death from cardiovascular causes, myocardial infarction, stroke or non-CNS systemic embolism

    Time frame: 15 months

  7. The number of participants died from cardiovascular or non-cardiovascular causes

    Time frame: 12 months

  8. The number of participants died from cardiovascular or non-cardiovascular causes

    Time frame: 15 months

  9. The number of participants with a composite of stroke and non-CNS systemic embolism

    Time frame: 12 months

  10. The number of participants with a composite of stroke and non-CNS systemic embolism

    Time frame: 15 months

  11. The number of participants with any stroke (including ischemic, hemorrhagic and unknown types)

    Time frame: 12 months

  12. The number of participants with any stroke (including ischemic, hemorrhagic and unknown types)

    Time frame: 15 months

  13. The number of participants with an ischaemic stroke

    Time frame: 12 months

  14. The number of participants with an ischaemic stroke

    Time frame: 15 months

  15. The number of participants with a hemorrhagic stroke

    Time frame: 12 months

  16. The number of participants with a hemorrhagic stroke

    Time frame: 15 months

  17. The number of participants with a transient ischemic attack

    Time frame: 12 months

  18. The number of participants with a transient ischemic attack

    Time frame: 15 months

  19. The number of participants with a composite of definite or probable stent thrombosis

    Time frame: 12 months

  20. The number of participants with a composite of definite or probable stent thrombosis

    Time frame: 15 months

  21. The number of participants with a definite stent thrombosis

    Time frame: 12 months

  22. The number of participants with a definite stent thrombosis

    Time frame: 15 months

  23. The number of participants with a hospitalization

    Time frame: 12 months

  24. The number of participants with a hospitalization

    Time frame: 15 months

  25. The number of participants with a composite of death or hospitalization

    Time frame: 12 months

  26. The number of participants with a composite of death or hospitalization

    Time frame: 15 months

  27. The number of participants with any target lesion revascularization

    Time frame: 12 months

  28. The number of participants with any target lesion revascularization

    Time frame: 15 months

  29. The number of participants with any target vessel revascularization

    Time frame: 12 months

  30. The number of participants with any target vessel revascularization

    Time frame: 15 months

  31. The number of participants with any revascularization

    Time frame: 12 months

  32. The number of participants with any revascularization

    Time frame: 15 months

  33. The number of all bleeding events, also adjudicated according to Bleeding Academic Research Consortium, Thrombolysis in Myocardial Infarction or Global Use of Strategies to Open Occluded Coronary Arteries scales

    The BARC is scaled from 0 to 5, with higher scores indicating worse outcomes, the TIMI from minor to major to fatal bleeding, and the GUSTO from mild to moderate to severe or life-threatening.

    Time frame: 12 months

  34. The number of all bleeding events, also adjudicated according to Bleeding Academic Research Consortium, Thrombolysis in Myocardial Infarction or Global Use of Strategies to Open Occluded Coronary Arteries scales

    The BARC is scaled from 0 to 5, with higher scores indicating worse outcomes, the TIMI from minor to major to fatal bleeding, and the GUSTO from mild to moderate to severe or life-threatening.

    Time frame: 15 months

  35. Transfusion rates both in patients with and/or without clinically detected overt bleeding

    Time frame: 12 months

  36. Transfusion rates both in patients with and/or without clinically detected overt bleeding

    Time frame: 15 months

  37. The number of participants with a major adverse cardiac or cerebral events (MACCE), defined as the composite of death from any cause, myocardial infarction, stroke or non-central nervous system (non-CNS) systemic embolism

    Time frame: 15 months

07

Study locations

16 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2027, 48 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 48 months is close to that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2023
First posted
Jul 21, 2023
StartActual
Dec 18, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. 10 sites changed recruiting status (8 now recruiting, 2 now withdrawn)
Show 10 sites
  • Hartcentrum Hasselt · Hasselt, BelgiumNot yet recruiting→Recruiting
  • CHU Nîmes · Nîmes, FranceNot yet recruiting→Recruiting
  • Universitätsklinikum Frankfurt/Main · Frankfurt am Main, GermanyNot yet recruiting→Recruiting
  • Klinikum Friedrichshafen · Friedrichshafen, GermanyNot yet recruiting→Withdrawn
  • Ospedale Ferrarotto · Catania, ItalyNot yet recruiting→Recruiting
  • IRCCS Humanitas · Milan, ItalyNot yet recruiting→Recruiting
  • UMC public · Amsterdam, NetherlandsNot yet recruiting→Recruiting
  • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu · Poznan, PolandNot yet recruiting→Withdrawn
  • Hospital Universitario Marques de Valdecilla · Santander, SpainNot yet recruiting→Recruiting
  • Imperial College London · London, United KingdomNot yet recruiting→Recruiting
Show 3 added (3 Switzerland)
  • Kantonsspital Baselland Liestal · Liestal, Switzerland
  • Kantonsspital Aarau · Aarau, Switzerland
  • HOCH Health Ostschweiz, Kantonsspital St.Gallen · Sankt Gallen, Switzerland
Nov 16, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • Klinikum Friedrichshafen · Friedrichshafen, GermanyContact removed s•••@medizincampus.de
  • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu · Poznan, PolandContact removed m•••@skpp.edu.pl
  • Inselspital, Bern University Hospital, Department of Cardiology · Bern, SwitzerlandContact a•••@insel.ch · •••1916→m•••@insel.ch · •••4778
  • University Hospital Zürich · Zurich, SwitzerlandContact •••0597→•••0597
Nov 16, 2026
Title
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing SupraflexDrug-eluting Stent Implantation
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    3 sites added. 10 sites changed recruiting status (8 now recruiting, 2 now withdrawn)
    Show 10 sites
    • Hartcentrum Hasselt · Hasselt, BelgiumNot yet recruiting→Recruiting
    • CHU Nîmes · Nîmes, FranceNot yet recruiting→Recruiting
    • Universitätsklinikum Frankfurt/Main · Frankfurt am Main, GermanyNot yet recruiting→Recruiting
    • Klinikum Friedrichshafen · Friedrichshafen, GermanyNot yet recruiting→Withdrawn
    • Ospedale Ferrarotto · Catania, ItalyNot yet recruiting→Recruiting
    • IRCCS Humanitas · Milan, ItalyNot yet recruiting→Recruiting
    • UMC public · Amsterdam, NetherlandsNot yet recruiting→Recruiting
    • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu · Poznan, PolandNot yet recruiting→Withdrawn
    • Hospital Universitario Marques de Valdecilla · Santander, SpainNot yet recruiting→Recruiting
    • Imperial College London · London, United KingdomNot yet recruiting→Recruiting
    Show 3 added (3 Switzerland)
    • Kantonsspital Baselland Liestal · Liestal, Switzerland
    • Kantonsspital Aarau · Aarau, Switzerland
    • HOCH Health Ostschweiz, Kantonsspital St.Gallen · Sankt Gallen, Switzerland
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Klinikum Friedrichshafen · Friedrichshafen, GermanyContact removed s•••@medizincampus.de
    • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu · Poznan, PolandContact removed m•••@skpp.edu.pl
    • Inselspital, Bern University Hospital, Department of Cardiology · Bern, SwitzerlandContact a•••@insel.ch · •••1916→m•••@insel.ch · •••4778
    • University Hospital Zürich · Zurich, SwitzerlandContact •••0597→•••0597
    Title Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing SupraflexDrug-eluting Stent Implantation
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05955365
Collaborators
Sahajanand Medical Technologies Limited
Responsible party
Sponsor
First posted
Jul 21, 2023
Start date
Dec 18, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Stephan Windecker, Prof.
Contact
Stephan.Windecker@insel.ch
+41 31 632 44 97
Marco Valgimigli, Prof
Contact
Marco.Valgimigli@eoc.ch
+41 91 805 31 11
Stephan Windecker, Prof
principal investigator · Bern University Hospital, Department of Cardiology
Marco Valgimigli, Prof
principal investigator · Cardiocentro Ticino Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: P2Y12 Inhibitor

Start the discussion